Ruxolitinib

證據等級: L5

預測適應症: 10 個

The evidence pack contains 10 TxGNN-predicted indications ranging from L5 (no evidence) to L2 (clinical study + Phase 3 trial). The top-ranked TxGNN prediction (uterine corpus PEComa, score 99.73%) has zero supporting evidence. This report focuses on infection-associated hemophagocytic syndrome — the highest-evidence prediction (L2) with the most actionable recommendation — while providing a full landscape summary of all predictions.

Ruxolitinib: From Myeloproliferative Neoplasms to Infection-Associated Hemophagocytic Syndrome

One-Sentence Summary

Ruxolitinib is a selective JAK1/2 inhibitor established in the treatment of myeloproliferative neoplasms, working by blocking aberrant JAK-STAT signaling that drives abnormal cell proliferation and systemic inflammation. The TxGNN model predicts it may be effective for infection-associated hemophagocytic syndrome (HPS/HLH) — a life-threatening cytokine storm disorder triggered by viral or bacterial pathogens — with 2 registered clinical trials and 20 publications currently supporting this direction, the strongest evidence among 10 predicted indications evaluated in this evidence pack.

Evidence pack scope: TxGNN identified 10 candidate repurposing indications for ruxolitinib. Seven are PEComa/TSC-spectrum rare tumors (Ranks 1–4, 7) or rhabdoid tumor (Rank 6) with L5 evidence only. Liposarcoma (Rank 5) has L4 mechanistic evidence. Malignancy-associated HLH (Rank 9) carries L3 evidence. Infection-associated HPS (Rank 10) is the sole indication reaching L2 with an actionable recommendation.

Quick Overview

Item	Content
Original Indication	No approved indication on record in Taiwan
Predicted New Indication	Hemophagocytic Syndrome Associated with an Infection
TxGNN Prediction Score	99.32%
Evidence Level	L2
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack. Based on analytical notes embedded throughout the repurposing rationale, ruxolitinib is a potent JAK1/2 inhibitor that simultaneously suppresses multiple pro-inflammatory cytokine axes — most critically IFN-γ (via JAK1/2–STAT1), IL-6 (via JAK1–STAT3), and IL-2/IL-15 (via JAK1/3–STAT5). This positions ruxolitinib as a broad cytokine storm modulator rather than a single-pathway blocker.

Infection-associated HPS/HLH develops when pathogens — predominantly Epstein-Barr virus, adenovirus, and certain bacteria — hijack T cell and macrophage activation, unleashing a catastrophic cytokine cascade. IFN-γ is the primary driver: it activates macrophages through JAK1/2–STAT1, which in turn produce more IFN-γ and IL-6 in a self-amplifying loop, leading to fever, pancytopenia, hyperferritinemia, hepatosplenomegaly, and multiorgan failure. The JAK1/2–STAT axis is the shared final signaling pathway for nearly every cytokine implicated in this process. Ruxolitinib blocks it at the source.

This mechanistic logic has been validated in multiple layers of evidence. Preclinical studies in perforin-deficient murine HLH models (PMID 31015190) confirmed that ruxolitinib reduces T cell activation, dampens IFN-γ downstream signaling, and decreases immunopathology. Combination studies in the same model further showed synergy with IFN-γ neutralization (PMID 37228616). Clinically, these findings translate into responses observed across pediatric EBV-HLH, adenovirus-associated post-transplant HPS, panniculitis-triggered HPS, infection-associated HPS in pregnancy, and AIDS-associated secondary HLH — spanning diverse trigger types and patient populations with consistent mechanistic logic.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07424222	Phase 1	Not Yet Recruiting	16	Pilot study of ruxolitinib for immune effector cell-associated HLH-like syndrome (IEC-HS) occurring after CAR-T therapy; evaluates safety, efficacy, optimal treatment duration, immunological response biomarkers, and CAR-T expansion dynamics post-ruxolitinib
NCT04424056	Phase 3	Unknown	216	Open-label randomized trial of anakinra and/or tocilizumab ± ruxolitinib in severe COVID-19-associated hyperinflammation (Stage 2b/3, CRP >200 mg/L, ARDS); directly tests ruxolitinib combination in a cytokine storm setting — final publication status requires confirmation

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34605776	2022	Consensus Guidelines	Critical Care Medicine	International multidisciplinary consensus guidelines for HLH recognition, diagnosis, supportive care, and treatment in ICU; establishes the diagnostic and management framework within which ruxolitinib is being evaluated
35344583	2022	Prospective Cohort	Blood	Ruxolitinib as first-line therapy for pediatric HLH with response-based treatment stratification (ChiCTR2000031702, n=50+); shows ruxolitinib's frontline viability and supports early JAK inhibition to prevent disease escalation
40665481	2025	Retrospective Cohort	British Journal of Haematology	Largest published comparison of RUX-based regimen (n=53) vs adjusted HLH-94 chemotherapy (n=42) in pediatric EBV-HLH; provides direct comparative efficacy and safety data for ruxolitinib vs standard-of-care
37787838	2023	Retrospective Cohort (n=12)	Annals of Hematology	Sintilimab combined with ruxolitinib as compassionate therapy for 12 adult EBV-HLH patients; demonstrates combination targeted immunotherapy strategy for refractory adult HLH with unsatisfactory overall survival on conventional therapy
37702780	2023	Review	Innere Medizin	Review of HLH management in ICU patients including ruxolitinib and emapalumab; discusses CAR-T–associated HLH as an emerging indication and frames JAK inhibition within evolving treatment algorithms
31943120	2020	Review	QJM	Comprehensive review of adult HLH diagnosis, triggers, and treatment; characterizes the high mortality burden and documents the limitations of HLH-94 in adult populations
38691058	2024	Case Series	Journal of Pediatric Hematology/Oncology	Emapalumab + ruxolitinib + dexamethasone for EBV-HLH with multiorgan damage and severe infection; illustrates a multi-target combination approach for cases refractory to both HLH-94 and ruxolitinib monotherapy
38984023	2024	Case Report	Translational Pediatrics	Ruxolitinib as salvage therapy for adenovirus-associated HPS occurring after haploidentical allogeneic HSCT; successful outcome in a rare post-transplant HLH scenario with limited treatment options
39620213	2024	Case Report	Frontiers in Immunology	Infection-associated HPS during pregnancy treated with ruxolitinib induction followed by HLH-94 protocol; notable evidence that ruxolitinib can be used in high-risk patients where cytotoxic chemotherapy carries additional risk
36533357	2022	Case Report	Journal of Peking University Health Sciences	Two cases of panniculitis-associated HPS effectively resolved with ruxolitinib; demonstrates efficacy in an atypical HPS trigger with autoimmune-inflammatory overlap

Taiwan Market Information

Ruxolitinib currently has no marketing authorizations in Taiwan. No approved products, indications, or dosage forms are on record with the Taiwan FDA.

Safety Considerations

Please refer to the package insert for safety information.

⚠️ Data Gap Notice: Taiwan package insert warnings, contraindications, and drug interaction data were not available in this evidence pack. These are classified as a Blocking data gap (DG001) that must be resolved before formal safety screening (Stage S1) can proceed.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Ruxolitinib's JAK1/2 inhibition directly and mechanistically targets the IFN-γ–driven cytokine storm cascade that defines infection-associated HPS/HLH. The growing clinical evidence base — spanning a frontline prospective cohort in Blood, the largest comparative pediatric cohort to date in British Journal of Haematology, multiple retrospective cohorts, an ongoing Phase 3 RCT (NCT04424056, n=216), and a forthcoming Phase 1 trial in CAR-T–associated HLH (NCT07424222) — establishes mechanistic-clinical consistency strong enough to justify cautious advancement under structured guardrails.

To proceed, the following is needed:

Confirm NCT04424056 final results — Phase 3 status is listed as "Unknown"; if results are positive, evidence level upgrades from L2 to L1, which significantly strengthens the repurposing case
Resolve Taiwan package insert data gap (DG001) — obtain and parse the 仿單 PDF from the TFDA website to complete safety screening and enable formal Stage S1 evaluation
Obtain full MOA data from DrugBank (DG002) — required to complete the mechanistic linkage analysis and document the JAK1/2 inhibition profile formally
Pursue Taiwan import or compassionate use registration — given zero current authorizations, a regulatory pathway must be identified before clinical availability can be established
Stratify evidence by HPS trigger type — EBV-HLH has the most data; develop a Taiwan-specific subgroup analysis plan to identify the most responsive patient population
Design a prospective pilot study or patient registry — to generate Taiwan-population–specific safety and efficacy data in infection-associated HPS cases
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.